Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4805167 | 0.81 | HDAC1 (0.54) | MAP2K1USP30SIRT2PDK1PDK2 | |
| SCHEMBL18112296 | 0.80 | MAP2K1 (0.51) | MAP2K1USP30SIRT2PDK1PDK2 | |
| SCHEMBL1503612 | 0.80 | HTT (0.58) | — | |
| SCHEMBL23466404 | 0.79 | GPR35 (0.53) | GPR35PDK1PDK2PDK3PDK4 | |
| SCHEMBL29758069 | 0.79 | GPR35 (0.53) | GPR35PDK1PDK2PDK3PDK4 | |
| SCHEMBL16924564 | 0.79 | CXCR1 (0.47) | MAP2K1USP30SIRT2PDK1PDK2 | |
| SCHEMBL20560202 | 0.78 | USP30 (0.47) | MAP2K1USP30SIRT2PDK1PDK2 | |
| SCHEMBL21138721 | 0.78 | HPGD (0.50) | MAP2K1GPR35MEN1KMT2A | |
| SCHEMBL29582812 | 0.77 | EGLN2 (0.53) | MAP2K1USP30PDK1PDK2PDK3 | |
| SCHEMBL21138715 | 0.77 | ALDH1A1 (0.57) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
| WO-2019115586-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | MAP2K1 3897/4885GPR35 1065/4885USP30 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.